Ambarella Inc vs Stryker Corporation — how do they compare? Ambarella Inc trades at $73.04 (market cap $3.39B), while Stryker Corporation trades at $332.53 (market cap $126.42B). The key difference: Stryker Corporation is far larger — about 37.3× Ambarella Inc's market cap, and Stryker Corporation pays a 1.07% dividend while Ambarella Inc pays none. Which is the better fit depends on your goals.
| AMBA | SYK | |
|---|---|---|
Market Cap | $3.39B | $126.42B |
Sector | Technology | Technology |
52-Week High | $95.51 | $403.53 |
52-Week Low | $48.65 | $282.58 |
Enterprise Value | $3.13B | $138.18B |
Dividend Yield | — | 1.07% |
Signals from Pluang's Aura AI — not financial advice
Ambarella (AMBA) trades at $77.30, down 1.38% on the day, with a bullish technical setup supported by moving averages and key resistance at $81. The company reported three consecutive quarterly EPS beats, with Q1 2027 earnings of $0.11 meeting estimates, while revenue grew 16.9% year-over-year to $100.4 million. A major catalyst is the $800+ million long-term edge AI agreement with Hanwha, signaling strong demand in physical AI markets. However, net income remains negative at -$117.13 million for 2025, though margins are improving.
Outlook: Wall Street is bullish with a $108.67 consensus price target (40% upside), driven by edge AI adoption and auto sector growth. Risks include persistent losses, competitive pressure from larger chipmakers, and execution challenges in scaling new AI contracts. The stock's valuation at 8.21x sales appears reasonable if revenue acceleration continues, but profitability remains key for sustained gains.
Stryker (SYK) trades at $329.78, up 0.82% on the day, with a bullish technical signal and strong analyst support. The stock shows robust fundamentals with a 63.83% gross profit margin and consistent earnings beats in recent quarters, despite a Q1 2026 miss attributed to a temporary cyber disruption. Recent news highlights the company's innovation and market position as a medtech leader.
The outlook remains positive with a consensus price target of $388.44, representing ~18% upside. Key risks include execution challenges post-cyber incident and competitive pressures, but strong cash flow and dividend growth support long-term value. Investor sentiment is buoyed by unchanged full-year guidance and healthy end-market demand.
Trailing returns across standard periods
Latest headlines on both assets
Ambarella is a semiconductor company specializing in low-power video compression and computer vision processors. Its chips power AI cameras for security, automotive safety, and robotics applications.
Read more on AMBA →Stryker is a global leader in medical technology, specializing in Orthopaedics, MedSurg, and Neurotechnology. It is renowned for its highly decentralized business model, which empowers 22 specialized business units to drive innovation and category leadership. With its market-leading Mako SmartRobotics™ platform and a relentless M&A strategy, Stryker provides a comprehensive ecosystem of connected surgical tools, implants, and digital solutions that improve both clinical and financial outcomes for hospitals worldwide.
Read more on SYK →